NCT05254119 (REGISTURK-LUNG) is a clinical trial in Non Small Cell Lung Cancer, sponsored by Mahmut Gumus.

Who is sponsoring NCT05254119?

NCT05254119 is sponsored by Mahmut Gumus.

What condition does NCT05254119 study?

NCT05254119 studies Non Small Cell Lung Cancer, Small-cell Lung Cancer.

Is NCT05254119 still recruiting?

NCT05254119 is currently active, enrolled. Last updated 4 April 2024.

Last reviewed 2024-04-04 · How we verify

NCT05254119: REGISTURK-LUNG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS

Active, enrolled Last updated 4 April 2024

What this trial tests

trial in Non Small Cell Lung Cancer in 6,000 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 December 2021

Primary endpoint
31 December 2024

28 February 2025

Quick facts

Lead sponsor	Mahmut Gumus
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	6,000
Start date	1 December 2021
Primary completion	31 December 2024
Estimated completion	28 February 2025
Sites	39 locations across Turkey (Türkiye)

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Small-cell Lung Cancer — all drugs for Small-cell Lung Cancer →

Sponsor

Mahmut Gumus

Who can join

18 and older, any sex, with Non Small Cell Lung Cancer or Small-cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05254119 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mahmut Gumus
Last refreshed: 4 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05254119.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing